NEOXpress, a novel TCR platform to target solid tumors
NEOXpress, a novel TCR platform to target solid tumors Read More »
BlueSphere Bio Data to be Presented at the 2022 Joint ASTCT + EBMT Basic and Translational Scientific Retreat
PITTSBURGH, PA, May 25, 2022 — BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a powerful TCR discovery platform and novel therapeutic candidates for patients with hematologic malignancies and solid tumors, today announced that Sawa Ito, M.D., Ph.D., was selected to provide an oral presentation during the 2022 Joint ASTCT + EBMT Basic
BlueSphere Bio Appoints Robert Keefe, Ph.D. as Chief Development Office
Dr. Keefe to lead the product development and manufacturing of BlueSphere Bio’s first clinical candidate, a TCR T-cell therapy directed against the miHA HA-1. PITTSBURGH, PA, April 26, 2022 — BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a powerful TCR discovery platform and novel therapeutic candidates for patients with hematologic malignancies and
BlueSphere Bio Appoints Robert Keefe, Ph.D. as Chief Development Office Read More »
BlueSphere Bio Data to be Presented at the 2022 American Association for Cancer Research Annual Meeting
PITTSBURGH, PA, March 15, 2022 — BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a revolutionary TCR discovery platform and novel therapeutic candidates for patients with hematologic malignancies and solid tumors, today announced that Sawa Ito, M.D., Ph.D., hematologist/oncologist at UPMC Hillman Cancer Center and Assistant Professor, Division of Hematology-Oncology and of Immunology
